Scarica l'app Stockscreener
0.20
21.52%
-0.010
Dopo l'orario di chiusura:
.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.21
Aprire:
$0.168
Volume 24 ore:
65,778
Relative Volume:
66.00
Capitalizzazione di mercato:
$N/A
Reddito:
-
Utile/perdita netta:
$-16.08M
Rapporto P/E:
-0.00581
EPS:
-34.43
Flusso di cassa netto:
$-11.54M
1 W Prestazione:
-21.52%
1M Prestazione:
-80.61%
6M Prestazione:
-86.27%
1 anno Prestazione:
-97.18%
Intervallo 1D:
$0.168
$0.21
Intervallo di 1 settimana:
$0.168
$0.21
Portata 52W:
$0.168
$0.21
Bio Path Holdings Inc Stock (BPTH) Company Profile
Nome
Bio Path Holdings Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BPTH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.20 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 40.54M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ATHE
Alterity Therapeutics Ltd Adr
|
4.75 | 63.36M | 0 | 0 | 0 | 0.00 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.31 | 37.83B | 2.35B | -269.70M | -75.39M | -2.09 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-11 | Iniziato | ROTH Capital | Buy |
| 2017-11-13 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-10 | Reiterato | Maxim Group | Buy |
| 2016-04-18 | Iniziato | Rodman & Renshaw | Buy |
| 2014-06-02 | Ripresa | Maxim Group | Buy |
| 2014-05-09 | Iniziato | Maxim Group | Buy |
Mostra tutto
Bio Path Holdings Inc Borsa (BPTH) Ultime notizie
When is Comtech's Q3 Earnings? Key Date and Conference Call Details Revealed - Stock Titan
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 | BPTH Stock News - GuruFocus
Oil-Dri Delivers Massive 16% Dividend Hike After 22 Years of Unbroken Growth - Stock Titan
Bio-Path's Breakthrough: Phase 2 Leukemia Drug Advances While New Cancer Treatments Show Promise - Stock Titan
Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan
Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - Insider Monkey
Q.ANT Debuts First Interactive Live Demonstration and New Benchmarks for Analog Photonic Computing at ISC 2025 - Newsfile
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipe - GuruFocus
Bio-Path's (BPTH) Price Target Reduced by Roth Capital Amid Pipeline Updates | BPTH Stock News - GuruFocus
Bio-Path Holdings Provides Clinical and Operational Update | BPT - GuruFocus
BPTH: Bio-Path's Latest Clinical Developments and Milestones | BPTH Stock News - GuruFocus
Bio-Path Holdings Provides Clinical and Operational Update - The Manila Times
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib - The Manila Times
Bio-Path Holdings Provides Clinical and Operational Update | BPTH Stock News - GuruFocus
Bio-Path Holdings, Inc. Provides Update on Clinical Development Progress and Pipeline Advances - Nasdaq
Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewswire Inc.
Colgate-Palmolive Reshapes Executive Team: Danone Deputy CEO Joins as Americas COO in Strategic Growth Push - Stock Titan
Cytokinetics Management Reveals Latest Updates at Jefferies Healthcare ConferenceLive Webcast Available - Stock Titan
Transcript : Bio-Path Holdings, Inc.Special Call - marketscreener.com
Toyota Signs Rising Latin Star Ela Taubert as Tour Sponsor: Major US Concert Series Coming - Stock Titan
Revolutionary AI Nose Technology Hits 85% Accuracy, Targets $76.5B SmellTech Market for Eldercare Crisis - Stock Titan
Biotech to AI: Bionoid Pharma Makes Bold Pivot with New Identity as AI Maverick Intel - Stock Titan
Lantronix Launches Revolutionary AI Network Manager for $400M Console Server Market at Cisco Live - Stock Titan
Oxford Industries Sets Q1 Earnings Date: Luxury Apparel Giant's First Quarter Results Coming June 11 - Stock Titan
Air Products CEO Set to Share Industry Outlook at Major Deutsche Bank Industrial Conference - Stock Titan
Rigel to Present at the Jefferies Global Healthcare Conference - Stock Titan
4DMT Leadership to Present Latest Biotech Advances at Two Major Healthcare Conferences in June - Stock Titan
Insmed CEO Takes Stage at Goldman Sachs Healthcare Conference: Key Updates Expected - Stock Titan
Crown LNG Holdings Limited Discloses Receipt of NASDAQ Notice - The Manila Times
Bio-Path Holdings to Host Corporate Update Conference Call on Ma - GuruFocus
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 | BPTH Stock News - GuruFocus
Bio-Path Holdings, Inc. to Host Live Conference Call on May 29, 2025, for Business Overview - Nasdaq
Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - The Manila Times
Bio-Path Holdings to Reveal Latest Progress on Cancer Drug Pipeline and New Obesity Treatment Program - Stock Titan
Acute Myeloid Leukemia Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight - openPR.com
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Procure Space ETF (UFO) Adds Unidentified Aerial Phenomena Risk Disclosure to Prospectus - The Globe and Mail
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
Bio-Path: Q1 Earnings Snapshot - CT Insider
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Bio-Path (BPTH) to Release Earnings on Wednesday - Defense World
PTC hits Huntington biomarker, but approval path still uncertain - biocentury.com
Small Interfering RNA (siRNA) Therapeutics Market Know the Scope and Trends - openPR.com
StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
Global Chronic Myeloid Leukemia (CML) Treatment Market To Expand At A CAGR Of 7% Reaching $$11.39 Billion B... - WhaTech
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treat - GuruFocus
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treatment | BPTH Stock News - GuruFocus
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - The Manila Times
Microbix Presenting at the 2025 Bloom Burton Conference - The Manila Times
Bio Path Holdings Inc Azioni (BPTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
3.89%
Capitalizzazione:
|
Volume (24 ore):